CurrentCentenePolicy MC.CP.MP.248

Facility-based Sleep Studies for Obstructive Sleep Apnea

Medical necessity criteria and coding guidance for facility-based polysomnography (PSG), split-night studies, and CPAP/BiPAP titration for adults (≥18) with suspected obstructive sleep apnea; governs Centene-affiliated health plans.

Policy Summary

PayerCentene

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material changes indicated

Effective Date

Next Review Date

Key ActionObtain prior authorization when requesting facility-based PSG, split-night study, or in‑lab PAP titration and document medical necessity and reasons HSAT is inappropriate.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥18age group governed

≤2allowed per rolling year

BMI ≥50facility PSG criterion

Not sufficientactigraphy stance

95807-95811supporting CPTs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Facility-Based Sleep Studies

Initial facility-based PSG or split-night study (Adults ≥18)

Covered when ALL of the following are met:

Initial PSG criteria: Member/enrollee has suspected obstructive sleep apnea

Section I.A

HSAT not appropriate: Portable or home sleep apnea testing (HSAT) is not appropriate due to one or more of the following: (1) HSAT services unavailable; (2) unable to properly operate or tolerate HSAT equipment and no helper available; (3) previous HSAT results negative or inadequate for diagnosis and/or autotitration of APAP; (4) chronic opioid use; (5) low pretest probability of OSA (normal BMI <30, normal airway Mallampati 1–2, no snoring, and normal neck circumference: <17 inches males, <16 inches females); (6) mission-critical worker where falling asleep at work would have major negative impact; (7) BMI ≥ 50 kg/m2; (8) presence of one or more specified comorbid risk factors AND signs/symptoms suggestive of moderate- to high-risk OSA),

Section I.B items 1–8 (see policy for full enumerated factors)

Repeat facility-based PSG or split-night study (Adults ≥18)

Covered when ALL of the following are met:

Base requirements: All of the criteria in section I.B are met

Section II.A

Study frequency limit: Requested study and any previous studies amount to two or less per rolling year<=2 per rolling year

Section II.B

Permitted reasons for repeat study: One or more of the following: (1) Oral appliance adjusted for fit and requires efficacy assessment; (2) Change of device due to intolerance; (3) Reassessment of PAP settings including continued symptoms despite documented adherence (≥4 hours/night for 70% of nights over 30 days); (4) Significant weight loss (>10%) to determine if PAP can be discontinued; (5) Significant weight gain or recurrent symptoms to assess reinstitution of PAP; (6) Postoperative assessment after upper airway surgery; (7) Remote history of OSA not on PAP needing re-establishment of diagnosis/initiation of CPAP; (8) New signs/symptoms after prior negative study (e.g., weight gain with symptoms, new nocturia); (9) Initial polysomnogram negative but clinical suspicion remains and a second study is considered

Section II.C items 1–9

Facility-based CPAP/BiPAP titration (Adults ≥18)

Covered when ONE of the following is met:

Titration criteria: A. Member meets criteria in section I for facility-based sleep study and has not attempted a home-based study for titration of APAP; OR B. Member was diagnosed with OSA during HSAT and there is evidence/documentation of failure of an APAP trial (e.g., downloaded compliance data)

Section III.A–B

Actigraphy

Actigraphy stance: Insufficient evidence to support the use of actigraphy testing alone for diagnosis of obstructive sleep apnea

Section IV; CPT 95803 listed as not supporting coverage

Actigraphy testing alone is considered insufficient evidence to support the diagnosis of obstructive sleep apnea (OSA). CPT 95803 (actigraphy testing, recording, analysis, interpretation, and report) is listed in this policy as not supporting coverage for the diagnosis of OSA.

When treating Medicaid members/enrollees, state Medicaid coverage provisions take precedence if they conflict with this clinical policy; providers should consult the applicable state Medicaid manual. Additionally, Medicare National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) must be reviewed and followed for Medicare members as applicable.

Coding Guidance

CPT codes that support coverageCPTCovered

95807	Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist.
95808	Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist.
95810	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist.
95811	Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist.

CPT codes that do not support coverageCPTNot Covered

95803

Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording).

inv-09: Epworth Sleepiness Scale

MeasureEpworth Sleepiness Scale (ESS)

ThresholdScore ≥ 10 supports signs/symptoms suggestive of moderate- to high-risk OSA

Role in policyUsed as one of the criteria indicating moderate- to high-risk OSA when combined with other risk factors or symptoms

inv-10: BMI

MeasureBody Mass Index (BMI)

ThresholdBMI ≥ 50 kg/m2 listed as criterion favoring facility-based PSG

Role in policy

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization and Medical Necessity

Prior authorization is required when facility-based PSG, split-night study, or in-lab PAP titration is requested and medical necessity must be documented. This clinical policy guides medical necessity determinations which inform coverage decisions and any required prior authorization; providers should submit supporting documentation with prior authorization requests.

Submit documentation that the member meets the applicable medical necessity criteria in the policy (see Section I–III).
Include prior study reports, HSAT results (if performed), APAP download/compliance data when claiming APAP failure, and any relevant clinical notes.
For Medicaid members, follow state Medicaid manual requirements where they differ from this policy.

Documentation Required

Document Medical Necessity and HSAT Unsuitability

Document why HSAT is not appropriate when requesting a facility-based PSG; include one or more of the acceptable reasons from the policy to support medical necessity.

Background

Obstructive sleep apnea (OSA) is the most common form of sleep-disordered breathing and is caused by recurrent upper airway collapse during sleep, leading to daytime sleepiness and increased cardiometabolic risk. Polysomnography (PSG) is the comprehensive, in‑lab standard for diagnosis and for CPAP/BiPAP titration, while home sleep apnea testing (HSAT) is an alternative for selected adults without significant comorbidities. Facility-based titration is considered medically necessary when criteria are met or when HSAT-diagnosed OSA demonstrates failure of an APAP trial documented by objective data (for example, downloaded compliance data).

Definitions

inv-22: Polysomnography (PSG)

DefinitionPolysomnography (PSG) is the continuous and concurrent monitoring and recording of physiological parameters of sleep including sleep staging, respiratory flow and effort, pulse oximetry, and ECG, performed with physician evaluation and technologist attendance for diagnosis and PAP titration.

Typical useUsed for comprehensive diagnosis of sleep disorders (including OSA) and for in-lab CPAP/BiPAP titration (full-night or split-night studies).

AdvantageMeasures multiple physiologic signals (sleep stages, respiratory variables, oximetry) providing higher sensitivity especially in patients with comorbidities or low pretest probability.

inv-23: Home Sleep Apnea Testing (HSAT)

DefinitionHome Sleep Apnea Testing (HSAT) refers to unattended out-of-laboratory sleep testing (device types 3 and 4) that measures fewer physiologic variables than PSG.

Policy Revision History

12/23policy_revisionLatest

Policy developed with internal and external specialist review; Coding Implications revision logged and document marked with Date of Last Revision 12/23.

Policy Summary

PayerCentene

PolicyFacility-based Sleep Studies for Obstructive Sleep Apnea

Policy CodePolicy MC.CP.MP.248

Change TypeNo material changes indicated

Effective Date

Next Review Date

Key ActionObtain prior authorization when requesting facility-based PSG, split-night study, or in‑lab PAP titration and document medical necessity and reasons HSAT is inappropriate.

SourceLink

On This Page

Specifically identifies patients for whom HSAT may be inappropriate and facility PSG is preferred

inv-11: Neck circumference

MeasureNeck circumference

ThresholdLess than 17 inches (biological males) or less than 16 inches (biological females) used in defining low pretest probability

Role in policyNormal/low neck circumference contributes to low pretest probability of OSA, favoring facility PSG over HSAT

Common acceptable reasons: HSAT unavailable; member unable to operate HSAT equipment and no assistant available; prior HSAT negative or inadequate; chronic opioid use; low pretest probability limitations of HSAT; mission-critical occupation; extreme obesity (BMI ≥ 50 kg/m2); significant cardiopulmonary, neurologic, or other risk factors listed in the policy.

Prior Authorization

Titration After APAP Failure

Facility-based titration is allowed when the member meets facility-based PSG criteria or when OSA was diagnosed by HSAT and there is documentation of APAP trial failure (for example, APAP download showing inadequate control or intolerance). Providers should include APAP downloaded data and documentation of attempts in the prior authorization or claim.

If APAP trial failed, include device download demonstrating failure (e.g., residual events, poor adherence, or intolerance).
If titration is requested without prior HSAT, document why a home-based titration was not attempted or not appropriate.

Documentation Required

Documentation for Repeat Studies

For repeat facility-based PSG or split-night studies, document that all initial-study criteria are met and that the total number of facility-based sleep studies (requested plus prior) is two or fewer within a rolling 12-month period. Provide a clinical rationale for the repeat study tied to one of the policy indications (e.g., device change, inadequate response, significant weight change, postoperative assessment).

State the number of prior facility-based sleep studies in the past 12 months and include dates and reports.
Link the repeat study request to one of the policy-specified indications (see section II.C).

Denial Risk

Unsupported Code Risks Denial

Claims submitted with CPT 95803 (actigraphy testing) do not support coverage under this policy. Use of unsupported codes may lead to claim denial; inclusion or exclusion of codes in this policy does not guarantee coverage by all health plans.

Do not rely on actigraphy (CPT 95803) alone to establish medical necessity for OSA testing per this policy.
If submitting ancillary or investigational testing, provide rationale and check plan-specific coverage rules.

Note

Coverage and Benefit Conditions

Coverage decisions and benefit administration are subject to the member's contract, plan terms, exclusions, limitations, and applicable state Medicaid provisions. This clinical policy does not supersede contractual benefit language or legal/regulatory requirements.

Verify member eligibility, benefits, and any plan-level prior authorization procedures before scheduling services.
For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this policy.

Appropriate for selected high-pretest-probability, uncomplicated adult patients without significant cardiorespiratory disease or suspected non-respiratory sleep disorders.

Device noteType 3 devices (4–7 variables) are preferred over type 4 (1–3 variables) due to additional measured variables and higher adequacy.

inv-24: Definition of 'Health Plan'

Definition'Health Plan' means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates.

ImplicationThis clinical policy is adopted and applied by Centene-affiliated Health Plans and guides medical necessity determinations and coverage decisions.

LimitationsPolicy guidance does not constitute a contract or guarantee of payment; coverage is subject to plan terms, state/federal requirements, and Health Plan administrative procedures.